<DOC>
	<DOCNO>NCT01747655</DOCNO>
	<brief_summary>Patients advance Parkinson 's Disease experience range severity motor fluctuation . The rationale Post Marketing Observational Study demonstrate benefit Duodopa treatment Parkinson 's Disease patient enter advanced stage disease whose motor fluctuation become troublesome complicate management oral therapy . The aim post-marketing observational study assess effect Duodopa treatment activity daily live advance Parkinson 's Disease participant characterise either 2-4 hour `` '' time 2 hour non-troublesome troublesome dyskinesia daily , support Unified Parkinson 's Disease Rating Scale Total Score best `` '' state least 40 point baseline .</brief_summary>
	<brief_title>A Post Marketing Observational Study Activities Daily Living Advanced Parkinson 's Disease Patients With Early Troublesome Motor Fluctuations Treated With Duodopa - Multi-country Study</brief_title>
	<detailed_description>Data record visit closely align plan period Visit 0 ( V0 ) : Baseline ( After decision use temporary naso-duodenal tube ( approximately 2-14 day ) signature Patient Authorization/Informed Consent Form ) ; Visit 1 ( V1 ) : At discharge hospital ; Visit 2 ( V2 ) : 3 month discharge ; Visit 3 ( V3 ) : 6 month discharge ; Visit 4 ( V4 ) : 12 month discharge . All participant temporary naso-duodenal tube use initially infusion pump determine participant respond favorably method treatment optimize dose Duodopa permanent treatment start . Participants choose treatment Duodopa temporary naso-duodenal test phase consider Standard Care group . Participants go select Apomorphine pump Deep Brain Stimulation stage eligible continue group continue observational period study . Participants continue Duodopa treatment temporary naso-duodenal test phase Duodopa group .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<criteria>Has advance levodoparesponsive Parkinson 's disease The decision treat Duodopa make physician accordance local label ( Summary Product Characteristics ; product label ) prior decision approach patient participate study Parkinson 's Disease ( PD ) medicinal treatment unchanged least four week prior baseline Takes oral medication four time daily Either 24 hour `` '' time 2 hour nontroublesome troublesome dyskinesia daily support Unified Parkinson 's Disease Rating Scale ( UPDRS ) Total Score best `` '' state least 40 point baseline ; base document medical history Use Deep Brain Stimulation ( DBS ) , Apomorphine pump Duodopa treatment prior baseline visit Severe dementia base MiniMental State Examination ( MMSE ) &lt; 24</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Early Observational Advanced</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>